ERBB2 and gastroesophageal junction adenocarcinoma: An ongoing Phase 2 clinical trial (NCT05034887) is exploring Trastuzumab Deruxtecan (T‐DXd) in neoadjuvant and adjuvant treatment for HER‐2 positive gastric and GEJ adenocarcinoma.